Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 301–400 of 1,017
deGoma, E. M., Leeper, N. J., & Heidenreich, P. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.086 · Cited by 133
Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization
Zhu, T., & Goodarzi, M. O. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab757 · Cited by 126
Piccini, J. P., Whellan, D. J., Berridge, B. R., Finkle, J. K., Pettit, S. D., Stockbridge, N., Valentin, J., Vargas, H. M., & Krucoff, M. W. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.007 · Cited by 125
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
“Notably, ILLUMINATE included patients at high cardiovascular risk and all participants of the dal-OUTCOMES trial had suffered a recent acute coronary syndrome.(11,12) Therefore, the aim of the present study was to investigate whether CAD at baseline affects the prognostic value of HDL cholesterol for cardiovascular mo…”
BackgroundResultStatins stimulate atherosclerosis and heart failure: pharmacological mechanisms
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1011125 · Cited by 122
“Recently, cholesterol ester transport protein inhibitors were developed and they were effective in lowering LDL-C/HDL-C ratios but they were essentially ineffective in preventing CHD [1].”
BackgroundDyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 156
“Albeit high HDL-C levels are protective against cardiovascular events in the general population [6,7], clinical trials failed to demonstrate that pharmacologic interventions, such as niacin, reduce the risk of cardiovascular events [67-70].”
High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis
Nofer, J., Brodde, M. F., & Kehrel, B. E. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05377.x · Cited by 122
“effects of medication with an HDL-elevating compound (torcetrapib) on cardiovascular mortality have been reported.(115) Although treatment with torcetrapib led to a considerable increase in plasma HDL-C in that study, the functional properties of HDL in treated subjects with respect to modulating platelet reactivity r…”
BackgroundYasuda, T., Ishida, T., & Rader, D. J. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0934 · Cited by 122
Patel, P. J., Khera, A. V., Jafri, K., Wilensky, R. L., & Rader, D. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.030 · Cited by 131
How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators
Cooney, M. T., Dudina, A., De Bacquer, D., Fitzgerald, A., Conroy, R., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., et al. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283213140 · Cited by 121
Stabilization of atherosclerotic plaques: an update
Ylä‐Herttuala, S., Bentzon, J. F., Daemen, M. J. A. P., Falk, E., García‐García, H. M., Herrmann, J., Hoefer, I. E., Jauhiainen, S., Jukema, J. W., Krams, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht301 · Cited by 138
Sacks, F. M., & Jensen, M. K. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.307025 · Cited by 117
Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
Hafiane, A. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030026 · Cited by 144
McGraw, A. P., Bagley, J., Chen, W., Galayda, C., Nickerson, H., Armani, A., Caprio, M., Carmeliet, P., & Jaffe, I. Z. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000018 · Cited by 125
Coffee Consumption Enhances High-Density Lipoprotein-Mediated Cholesterol Efflux in Macrophages
Uto‐Kondo, H., Ayaori, M., Ogura, M., Nakaya, K., Ito, M., Suzuki, A., Takiguchi, S., Yakushiji, E., Terao, Y., Ozasa, H., et al. (2010) · Circulation Research · doi:10.1161/circresaha.109.206615 · Cited by 132
Illuminating HDL — Is It Still a Viable Therapeutic Target?
Rader, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejme0707210 · Cited by 120
Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action
Nagao, M., Nakajima, H., Toh, R., Hirata, K., & Ishida, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17025 · Cited by 133
Rysz, J., Gluba-Brzózka, A., Rysz-Górzyńska, M., & Franczyk, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020601 · Cited by 136
Hayward, R. A., & Krumholz, H. M. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964676 · Cited by 123
Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery
Damiano, M. G., Mutharasan, R. K., Tripathy, S., McMahon, K. M., & Thaxton, C. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.013 · Cited by 124
“However, to date there is very little evidence to suggest that these drugs are effective in reducing clinical endpointswhich are consequences of atherosclerosis, such as myocardial infarction [39,40].”
Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides
Tervaert, J. W. C. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.12.004 · Cited by 124
Cao, G., Beyer, T. P., Zhang, Y., Schmidt, R. J., Chen, Y. Q., Cockerham, S. L., Zimmerman, K. M., Karathanasis, S. K., Cannady, E. A., Fields, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m018069 · Cited by 116
HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
Bonacina, F., Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Cells · doi:10.3390/cells10051061 · Cited by 130
“Data from the ILLUMINATE trial showed that raising HDL-C with torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, resulted in an increased risk of infectious disease-related deaths compared to placebo [7].”
MethodTricoci, P., D’Andrea, D. M., Gurbel, P. A., Yao, Z., Cuchel, M., Winston, B., Schott, R. J., Weiss, R., Blazing, M. A., Cannon, L., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002171 · Cited by 122
“Fibrates and niacin typically achieve <10% elevation,(15) while dalcetrapib and torcetrapib achieved only 10% to 25% elevation.(10,11) Additionally, the predominant change caused by these agents is an increase in HDL particle size, and larger HDL particles do not efficiently interact with the ABCA1 transporter.”
BackgroundSelf-citationTardy, C., Goffinet, M., Boubekeur, N., Ackermann, R., Sy, G., Bluteau, A., Cholez, G., Keyserling, C., Lalwani, N., Paolini, J. F., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.018 · Cited by 114
Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease
Kohan, A. B. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000136 · Cited by 113
Nicholls, S. J., Ruotolo, G., Brewer, H. B., Kane, J. P., Wang, M.-D., Krueger, K. A., Adelman, S. J., Nissen, S. E., & Rader, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.013 · Cited by 114
“Torcetrapib monotherapy resulted in increased total CEC at the 60 mg/day dose used in the cardiovascular outcomes study ILLUMINATE (Investigation of Lipid Level management to Understand its iMpact IN ATherosclerotic Events) (9) and at the 120mg/day dose (28) in proportion to the magnitude of HDL-C increase with these…”
MethodHDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
DiDonato, J. A., Huang, Y. R., Aulak, K. S., Even‐Or, O., Gerstenecker, G. S., Gogonea, V., Wu, Y., Fox, P. L., Tang, W. H. W., Plow, E. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002624 · Cited by 125
Hahn, B. H., Grossman, J. M., Ansell, B. J., Skaggs, B. J., & McMahon, M. A. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2471 · Cited by 129
Future Therapeutic Directions in Reverse Cholesterol Transport
Khera, A. V., & Rader, D. J. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0080-0 · Cited by 111
microRNAs in lipoprotein metabolism and cardiometabolic disorders
Rotllan, N., Price, N., Pati, P., Goedeke, L., & Fernández-Hernando, C. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.025 · Cited by 100
Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease
Srivastava, R. A. K. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3165-z · Cited by 124
“The very first CETP inhibitor, torcetrapib [82], despite showing massive increase in HDL concentration in ILLUMINATE clinical trial, did not show any benefit in outcome studies, possibly due to high aldosterone levels [83, 84].”
Yamashita, S., Bujo, H., Arai, H., Harada-Shiba, M., Matsui, S., Fukushima, M., Saito, Y., Kita, T., & Matsuzawa, Y. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e610 · Cited by 110
Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
Graham, I. M., Cooney, M. T., Bradley, D., Dudina, A. L., & Reiner, Ž. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0313-7 · Cited by 121
“The ILUMINATE trial of torcetrapib had to be terminated early due to a 66% increase in total mortality in the active treatment group [58].”
Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis
Yarmolinsky, J., Bonilla, C., Haycock, P., Langdon, R., Lotta, L. A., Langenberg, C., Relton, C. L., Lewis, S. J., Evans, D. M., Smith, G. D., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy081 · Cited by 116
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D., & Robinson, J. G. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp601 · Cited by 109
The Changing Face of HDL and the Best Way to Measure It
Karathanasis, S. K., Freeman, L. A., Gordon, S. M., & Remaley, A. T. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.257725 · Cited by 109
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
The versatility of HDL: a crucial anti‐inflammatory regulator
Säemann, M. D., Poglitsch, M., Kopecky, C., Haidinger, M., Hörl, W. H., & Weichhart, T. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02361.x · Cited by 120
Kratzer, A., Giral, H., & Landmesser, U. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu139 · Cited by 109
Bell, G. A., Mora, S., Greenland, P., Tsai, M. Y., Gill, E., & Kaufman, J. D. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308193 · Cited by 118
High density lipoprotein cholesterol and cancer: Marker or causative?
Pirro, M., Ricciuti, B., Rader, D. J., Catapano, A. L., Sahebkar, A., & Banach, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.06.001 · Cited by 116
Correlation without a cause: an epidemiological odyssey
Davey Smith, G., & Phillips, A. N. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa016 · Cited by 107
The Effect of Alcohol on Blood Pressure and Hypertension
Fuchs, F. D., & Fuchs, S. C. P. C. (2021) · Current Hypertension Reports · doi:10.1007/s11906-021-01160-7 · Cited by 137
Novel metabolic biomarkers of cardiovascular disease
Jensen, M. K., Bertoia, M. L., Cahill, L. E., Agarwal, I., Rimm, E. B., & Mukamal, K. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.155 · Cited by 117
HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk
Girona, J., Amigó, N., Ibarretxe, D., Plana, N., Rodríguez-Borjabad, C., Heras, M., Ferré, R., Gil, M., Correig, X., & Masana, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133151 · Cited by 127
Zhang, L., Kamanna, V. S., Zhang, M. C., & Kashyap, M. L. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700426-jlr200 · Cited by 117
“cause of increased cardiovascular morbidity (25).”
Trinder, M., Wang, Y., Madsen, C. M., Ponomarev, T., Bohunek, L., Daisely, B. A., Kong, H. J., Blauw, L. L., Nordestgaard, B. G., Tybjærg‐Hansen, A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048568 · Cited by 121
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Navar, A. M., Nissen, S. E., Harada-Shiba, M., Curcio, D. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415820 · Cited by 103
Self-citationCui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 143
“The therapeutic journey of CETP inhibition has undergone significant evolution: early inhibitors like torcetrapib demonstrated potent HDL-C elevation and LDL-C reduction, yet failed due to off-target toxicity including aldosterone-mediated hypertension [267].”
High-Density Lipoproteins and Apolipoprotein A1
van der Vorst, E. P. C. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-41769-7_16 · Cited by 123
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 127
Self-citationNovel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 119
Haase, C. L., Tybjærg-Hansen, A., Grande, P., & Frikke-Schmidt, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0450 · Cited by 104
“Furthermore, clinical trials have shown that cholesteryl ester transfer protein inhibition that raises HDL cholesterol increases coronary disease (38).”
BackgroundSofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.865444 · Cited by 104
Self-citationRitsch, A., Scharnagl, H., Eller, P., Tancevski, I., Duwensee, K., Demetz, E., Sandhofer, A., Boehm, B. O., Winkelmann, B. R., Patsch, J. R., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.875013 · Cited by 104
Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=
Sviridov, D., Mukhamedova, N., T. Remaley, A., Chin-Dusting, J., & Nestel, P. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e571 · Cited by 104
DuPont, J. J., & Jaffe, I. Z. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0009 · Cited by 110
Cholesteryl ester transfer protein and its inhibitors
Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J., & Rye, K.-A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082735 · Cited by 104
“not known with certainty, but it may have been the consequence of serious off-target adverse effects of the drug (70), including increased blood pressure, increased synthesis”
BackgroundSelf-citationWong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 106
High-density lipoproteins and immune response: A review
Grao‐Cruces, E., Lopez-Enriquez, S., Martín, M. E., & la Paz, S. M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.009 · Cited by 114
Hima Bindu, G., Rao, V., & Kakkar, V. V. (2010) · Cholesterol · doi:10.1155/2011/274629 · Cited by 110
HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction
Zewinger, S., Speer, T., Kleber, M. E., Scharnagl, H., Woitas, R., Lepper, P. M., Pfahler, K., Seiler, S., Heine, G. H., März, W., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050482 · Cited by 103
Shea, S., Stein, J. H., Jorgensen, N. W., McClelland, R. L., Tascau, L., Shrager, S., Heinecke, J. W., Yvan-Charvet, L., & Tall, A. R. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311366 · Cited by 102
Self-citationAdorni, M. P., Ronda, N., Bernini, F., & Zimetti, F. (2021) · Cells · doi:10.3390/cells10030574 · Cited by 103
“Nevertheless, clinical studies have failed in proving their capacity to reduce CV risk [23].”
BackgroundMolecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions
Yamashita, S., Tsubakio‐Yamamoto, K., Ohama, T., Nakagawa-Toyama, Y., & Nishida, M. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5405 · Cited by 114
Johnston, T. P., Короленко, Т. А., Pirro, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.008 · Cited by 115
Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies
Furtado, J. D., Yamamoto, R., Melchior, J. T., Andraski, A. B., Gamez-Guerrero, M., Mulcahy, P., He, Z., Cai, T., Davidson, W. S., & Sacks, F. M. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311607 · Cited by 102
Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes
Clark, D. M., Nicholls, S. J., John, J. S., Elshazly, M. B., Ahmed, H. M., Khraishah, H., Nissen, S. E., & Puri, R. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0751 · Cited by 105
Soria-Florido, M. T., Schröder, H., Grau, M., Fitó, M., & Lassale, C. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.015 · Cited by 99
Costanzo, S., Castelnuovo, A. F. D., Donati, M. B., Iacoviello, L., & de Gaetano, G. (2010) · Circulation · doi:10.1161/circulationaha.109.865840 · Cited by 112
Kastelein, J. J. P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G. K., Al‐Saady, N., Koeijvoets, M., Hunter, J. A., Johnson‐Levonas, A. O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62115-2 · Cited by 102
Self-citationBarter, P. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.014 · Cited by 103
Self-citationRegieli, J. J., Jukema, J. W., Grobbee, D. E., Kastelein, J. J. P., Kuivenhoven, J. A., Zwinderman, A. H., van der Graaf, Y., Bots, M. L., & Doevendans, P. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn465 · Cited by 99
“Moreover, the safety of pharmacological CETP inhibition on top of statin therapy was recently questioned in view of the results of the Investigation of Lipid Level Management to Understand its impact in Atherosclerotic Events (ILLUMINATE) trial.(27) In this trial, in 15 067 symptomatic statin-treated coronary artery d…”
Self-citationKrishna, R., Bergman, A., Jin, B., Fallon, M. S., Côté, J., Hoydonck, P. V., Laethem, T., Gendrano, I., Dyck, K. V., Hilliard, D., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.109 · Cited by 101
Double Superhelix Model of High Density Lipoprotein
Wu, Z., Gogonea, V., Lee, X., Wagner, M. A., Li, X.-M., Huang, Y., Undurti, A., May, R. P., Haertlein, M., Moulin, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039537 · Cited by 100
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)
Potì, F., Simoni, M., & Nofer, J. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu136 · Cited by 115
“were randomly allocated to placebo or cholesterol ester transfer protein (CETP) inhibitors torcetrapib or dalcetrapib, respectively, revealed a lack of efficacy in reducing cardiovascular events despite the impressive HDL-C increase by 72 and 31–40%.(10,11) Though both niacin and CETP inhibitor trials were performed i…”
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., Sedlis, S. P., Kostuk, W. J., Spertus, J. A., Dada, M. R., CHAITMAN, B. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.051 · Cited by 112
“However, the CETP inhibitor torcetrapib was shown previously to increase mortality and, more recently, dalcetrapib was found to have no incremental benefit when added to statin therapy in ACS, despite significant HDL-C raising (34,35).”
BackgroundHigh-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 112
“Although binding to apoJ has been shown to expedite clearance of Ab40 across the bloodbrain barrier (Bell et al., 2007), whether apoA-I has any effect on brain-blood or blood-brain transport or perivascular drainage of Ab has not be determined.”
BackgroundCholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis
Trinder, M., Genga, K. R., Kong, H. J., Blauw, L. L., Lo, C., Li, X., Cirstea, M. S., Wang, Y., Rensen, P. C. N., Russell, J. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1157oc · Cited by 110
Biochemical characterization of cholesteryl ester transfer protein inhibitors
Ranalletta, M., Bierilo, K. K., Chen, Y., Milot, D., Chen, Q., Tung, E., Houde, C., Elowe, N. H., Garcia-Calvo, M., Porter, G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m007468 · Cited by 97
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
“To date, five CETP inhibitors have bene developed, of which two developmental programs have been halted due to either off-target toxicity (torcetrapib)(33) or futility (dalcetrapib)(34).”
BackgroundHDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 118
Dunder, L., Lind, P. M., Salihovic, S., Stubleski, J., Kärrman, A., & Lind, L. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112903 · Cited by 97
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Ogura, M., Hori, M., & Harada‐Shiba, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306665 · Cited by 98
Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96
Adipocytes, aldosterone and obesity-related hypertension
Dinh Cat, A. N., Friederich-Persson, M., White, A., & Touyz, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0025 · Cited by 96
“Clinical trials of the CETP inhibitors torcetrapib (Barter et al. 2007) and dalcetrapib (Schwartz et al.”
BackgroundDiDonato, J. A., Aulak, K., Huang, Y., Wagner, M., Gerstenecker, G., Topbas, C., Gogonea, V., DiDonato, A. J., Tang, W. H. W., Mehl, R. A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.556506 · Cited by 96
The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease
Brewer, H. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0163 · Cited by 102
Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions
Burgess, S., Freitag, D. F., Khan, H., Gorman, D. N., & Thompson, S. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108891 · Cited by 94
“Pharmaceutical agents which raise HDL-c levels have failed to show benefits for CAD and total mortality outcomes in clinical trials [21,22].”
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 100
Krauss, R. M., Wojnooski, K., Orr, J., Geaney, J. C., Pinto, C. A., Liu, Y., Wagner, J. A., Luk, J. M., Johnson-Levonas, A. O., Anderson, M. S., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m018010 · Cited by 95
Hwang, W.-C., Zhang, A., & Ramanathan, M. K. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.129 · Cited by 102
“(3) Φ Ψ = ⋅ ( ) ( ) ( ) Br v v C v R R”
de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W. A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M. G., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.761965 · Cited by 95
Annema, W., & von Eckardstein, A. (2016) · Translational Research · doi:10.1016/j.trsl.2016.02.008 · Cited by 94
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Vitali, C., Khetarpal, S. A., & Rader, D. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0940-0 · Cited by 101
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.